May 19, 2025
Atsena Reports LIGHTHOUSE data at ARVO
Gene therapy ATSN-201 shows good safety, efficacy signs in first part of the trial.
2025 Association for Research in Vision and Ophthalmology Annual Meeting
Related Articles
May 13, 2025
AAVantgarde Shares Clinical Data at ARVO 2025
Findings support continued development of gene therapies for Usher syndrome and Stargardt disease.
May 13, 2025
Optigo Wins People’s Choice Award at Eyecelerator 2025
At ARVO, the company presented preclinical data supporting the potential for 6-month dosing intervals in nAMD, DME, and RVO.
May 13, 2025
Real-World Data Supports Uveal Melanoma Test Combo
New data presented at ARVO 2025 confirms that adding PRAME status enhances the DecisionDx-UM test’s ability to predict metastasis.
May 13, 2025
Beacon Reports Interim Data on XLRP Therapy
At ARVO 2025, data presented from the DAWN phase 2 trial of the gene therapy showed promising improvements in visual function across several key measures.
May 8, 2025
EYP-1901 Shows 9-Month Disease Control in NPDR Patients
Despite missing the 12-month primary endpoint in PAVIA, the implant demonstrated early efficacy, guiding design for a planned phase 3 trial.
May 8, 2025
Isarna Reports Antisense Therapy Trial Data
The BETTER trial results support further testing of the experimental TGF-β2-blocking drug in retinal diseases, including wet AMD and DME.
May 8, 2025
Real-World Eylea HD Data Presented at ARVO
Initial data from nearly 40,000 patients demonstrate early visual improvements and reduced injection frequency.
May 8, 2025
New Data From ARVO Support Efficacy of Axitinib in NPDR
Results support further investigation of OTX-TKI as a long-acting treatment.